• About us
• Contact

Advertisement

Product › Details

LP2 (MOR107) lanthipeptide (Lanthio Pharma)

	Next higher product group	peptide-based drug_o
	Status	2015-05-07 development pp existent
	Organisation	Lanthio Pharma B.V.
	Group	Novartis (Group)

Record changed: 2023-07-10

Advertisement

More documents for peptide-based drug_o

• [1] Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA....
• [2] Bioxodes S.A.. (11/21/23). "Press Release: Bioxodes Closes €12 Million in Series A Funding Round". Gosselies....
• [3] Amolyt Pharma SAS. (1/6/23). "Press Release: Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group". Lyon & Cambridge, MA....
• [4] Relief Therapeutics Holding AG. (1/14/22). "Press Release: Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit". Geneva....
• [5] Relief Therapeutics Holding AG. (1/12/22). "Press Release: Relief Comments on Lawsuit Filed Against It by NeuroRx". Geneva....
• [6] Relief Therapeutics Holding AG. (11/30/21). "Press Release: Relief Therapeutics Announces Executive Changes". Geneva....
• [7] Relief Therapeutics Holding AG. (11/24/21). "Press Release: Relief Reports that Its U.S. Collaboration Partner Has Announced the U.S. Food and Drug Administration has Denied Breakthrough Designation for Aviptadil". Geneva....
• [8] Relief Therapeutics Holding AG. (10/7/21). "Press Release: Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100™ (Aviptadil)". Geneva....
• [9] Amolyt Pharma SAS. (9/16/21). "Press Release: Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners". Lyon & Cambridge, MA....
• [10] Relief Therapeutics Holding AG. (7/26/21). "Press Release: Relief Therapeutics Announces CHF 15 Million Private Placement (Ad Hoc)". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.